VX-210: BioAxone BioSciences, Inc. has licensed the complete patent portfolio protecting VX-210 (formerly Cethrin), including issued U.S. patents and patent applications (and foreign counterparts) to Vertex Pharmaceuticals. This portfolio encompasses composition of matter and therapeutic uses of VX-210.

Rho Kinase 2-selective  Inhibitors: BioAxone holds an issued patent on novel small molecule Rho kinase inhibitors. The company has a portfolio of pending applications for the ROCK2-selective inhibitors that are in development for angioma, stroke and glaucoma.